Secure CheckoutPersonal information is secured with SSL technology.
Free ShippingFree global shipping
No minimum order.
- Early age onset colorectal cancer
Swati G. Patel, Caitlin C. Murphy, Christopher H. Lieu, and Heather Hampel
2. Treatment-induced evolutionary dynamics in nonmetastatic locally advanced rectal adenocarcinoma
Seth I. Felder, Jason B. Fleming, and Robert A. Gatenby
2. Early colorectal cancer detection—Current and evolving challenges in evidence, guidelines, policy, and practices
Robert A. Smith, Stacey Fedewa, and Rebecca Siegel
4. Personalized nutrition for colorectal cancer
Kai Wang and Mingyang Song
5. Immunotherapy in colorectal cancer
Parul Agarwal, Dung T. Le, and Patrick M. Boland
6. Racial and ethnic disparities in colorectal cancer incidence and mortality
John M. Carethers
7. Genomic and epigenomic biomarkers in colorectal cancer: From diagnosis to therapy
Juan Ruiz-Bañobre and Ajay Goel
8. Field carcinogenesis for risk stratification of colorectal cancer
Dionne Rebello, Elliott Rebello, Matthew Custodio, Xixi Xu, Sanil Gandhi, and Hemant K. Roy
9. Modeling colorectal cancers using multidimensional organoids
Ibrahim M. Sayed, Amer Ali Abd El-Hafeez, Priti P. Maity, Soumita Das, and Pradipta Ghosh
10. Unraveling the genomic landscape of colorectal cancer through mutational signatures
Marcos Díaz-Gay and Ludmil B. Alexandrov
11. Epigenetic alterations in the gastrointestinal tract: Current and emerging use for biomarkers of cancer
William M. Grady
Novel Approaches to Colorectal Cancer, Volume 151 in the Advances in Cancer Research series, is composed of 11 reviews covering state-of-the-art research relating to the etiology, diagnosis, prevention and treatment of colorectal cancer. The book's chapters were written by recognized experts in the field, and include sections on molecular biomarkers in diagnosis and therapy, the interplay of diet, lifestyle, and the microbiome, early-age onset disease, mutational signature analysis, challenges in early detection, immunotherapy, organoid technology, the role of epigenetic alterations, disparities in minority populations, field carcinogenesis, and cancer as an evolutionary process.
Each of these topics provides novel insights and concepts on various aspects of the nature of colorectal cancer, offering new opportunities for the management of a major source of cancer incidence and mortality.
- Provides information on the timely nature of the included topics, which represent the most current concepts and approaches in cancer research
- Offers outstanding and original reviews on colorectal cancer research
- Provides the authority and expertise of the authors, all of whom are highly recognized and conducting state-of-the-art investigations in cancer, with this release focusing on colorectal cancer
Physicians who treat and manage patients diagnosed with colorectal and other cancers, basic scientists, translational researchers, and clinicians. Educators teaching undergraduate and graduate courses on cancer; corporate and private-sector entities developing new tools and strategies for preventing, detecting, and treating colorectal cancer; and to leaders in public health policy, including governmental, hospital-based, and the insurance industry, as they consider new strategies aimed at reducing the toll of the disease
- No. of pages:
- © Academic Press 2021
- 18th June 2021
- Academic Press
- Hardcover ISBN:
- eBook ISBN:
Dr. Berger is currently Director of Research & Outreach within the Colorectal Cancer Prevention Network at the University of South Carolina in Columbia, SC. He obtained a BA in Biology from the State University of NY at Buffalo in 1969, and a PhD in Biochemistry from Purdue University in 1974. In 1976. He began his career in cancer research at Roswell Park Cancer Institute in Buffalo, NY, where he was located until 1985 when he moved to the University of South Carolina. There, he was Professor in the Department of Biological Sciences until 2018, during which time he served as Department Chair (1996-2002) and was founding Director of the Center for Colon Cancer Research (2002-2018). For nearly 40 years, he ran a research laboratory focused on a variety of topics in mammalian molecular genetics, including colorectal cancer therapy and prevention. His efforts were generously supported by grants from the NIH, and resulted in over 130 articles in peer-reviewed scientific journals. Much of his research in colorectal cancer involved molecular mechanisms of resistance to chemotherapeutic agents. Most recently, Dr. Berger has carried out investigations involving the efficacy of colorectal cancer screening in the community setting, and has been actively engaged in community outreach efforts directed at increasing colorectal cancer awareness and screening, particularly within uninsured and medically underserved populations throughout the State of South Carolina. With the support of grants from foundations, as well as federal and state agencies, he has led the design and implementation of education and evidence-based screening programs across the State. He recently guest-edited a special focus issue of the journal COLORECTAL CANCER (Future Science Group, publisher) dedicated to early-onset colorectal cancer. Numerous graduate students and postdoctoral fellow trained in Dr. Berger’s laboratory, and went on to academic and/or corporate careers in scientific research. Among Dr. Berger’s awards for his efforts in the laboratory and the community are the SC Governor’s Award in Science (2005), the Distinguished Service Award from the SC Gastroenterology Association (2009), election as a Fellow of the American Association for the Advancement of Science (2010), the Laurel Award in Cancer Prevention from the Prevent Cancer Foundation (2012), and a Commendation (Senate Bill S.1260) from the South Carolina General Assembly (2018).
Research & Outreach Director, Colorectal Cancer Prevention Network, University of South Carolina, SC, USA
Dr. Boland is a gastroenterologist and Professor of Medicine at the University of California San Diego School of Medicine. He is from in upstate New York, USA, received a BA from The University of Notre Dame and an MD from Yale Medical School. He has a career-long research interest in colon cancer, specifically focusing on the genetic causes of colon cancer and familial cancer syndromes. Dr. Boland started studying familial colorectal cancer as a medical student, where he proposed a novel familial form of the disease in his MD thesis. His initial research was with Young S. Kim, MD, at UCSF, studying glycoprotein biochemistry in colorectal cancer. In 1990, at the U of Michigan, he turned his focus to the molecular genetics of colorectal cancer in a sabbatical in the HHMI with the geneticist Andrew Feinberg, MD, and resumed work on the hereditary form of colorectal cancer, which he had named “Lynch Syndrome” in 1984. He was among the first gastroenterologists to explore microsatellite instability (MSI) in cancer, and his laboratory developed the first in vitro models to study the basic biology of MSI and Lynch Syndrome. In recent years, he has contributed to our understanding of the genetic and epigenetic basis of colorectal cancer. Dr. Boland has been an active clinician, teacher, and mentor. Two of his former trainees are currently Department Chairs at Michigan and Stanford, and five have held endowed chairs. He has been funded continuously by NIH since 1979, has served on multiple NIH (and other) Study Sections and was the chair of the Clinical Integrative Molecular Gastroenterology Study Section from 2014 to 2016, and was on the Multisociety Task for on Colorectal Cancer from 2012-18. He has published over 400 papers, has an H-Index of 92, and has written authoritative chapters for several textbooks of Internal Medicine, Gastroenterology and Genetics. He was elected into the Association of American Physicians in 2001. He was honored by the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC) with their Lifetime Achievement Award in 2015. He was president of the American Gastroenterological Association (AGA) from 2011-2012, and was given the AGA Oncology Section Distinguished Mentor Award in 2011, the AGA Beaumont Prize for his research in 2015, and the AGA Friedenwald Medal in 2016. The University of Michigan has established an endowed Chair in his name, currently held by John Carethers, MD.
Professor of Medicine, University of California San Diego School of Medicine, USA
Elsevier.com visitor survey
We are always looking for ways to improve customer experience on Elsevier.com.
We would like to ask you for a moment of your time to fill in a short questionnaire, at the end of your visit.
If you decide to participate, a new browser tab will open so you can complete the survey after you have completed your visit to this website.
Thanks in advance for your time.